Study Summary: Efficacy and Safety of Intranasal Cenegermin in NAION This clinical trial is designed to test how well intranasal cenegermin works and how safe it is for adults with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). NAION is a type of eye disease causing sudden vision loss. The study involves two groups: one receiving cenegermin treatment and the other receiving a placebo (an inactive substance). Key Points:

• The study will include about 272 participants and takes place in multiple locations.
• Participants will be randomly assigned to receive either the treatment or placebo.
• Eligibility includes having NAION in one eye, with symptoms starting within 14 days of the first study dose.

Participants must have a certain level of vision in the affected eye and be able to have their eyes examined. People with NAION in both eyes, specific eye diseases, or other health conditions are not eligible. The study aims to ensure safety and effectiveness, helping doctors understand if cenegermin can help improve vision in NAION patients. Additional criteria apply, which can be discussed with a healthcare provider.